TY - JOUR
T1 - Evaluation of the Immune Response Induced by CoronaVac 28-Day Schedule Vaccination in a Healthy Population Group
AU - Escobar, Alejandro
AU - Reyes-López, Felipe E.
AU - Acevedo, Mónica L.
AU - Alonso-Palomares, Luis
AU - Valiente-Echeverría, Fernando
AU - Soto-Rifo, Ricardo
AU - Portillo, Hugo
AU - Gatica, Jimena
AU - Flores, Ivan
AU - Nova-Lamperti, Estefanía
AU - Barrera-Avalos, Carlos
AU - Bono, María Rosa
AU - Vargas, Leonardo
AU - Simon, Valeska
AU - Leiva-Salcedo, Elias
AU - Vial, Cecilia
AU - Hormazabal, Juan
AU - Cortes, Lina Jimena
AU - Valdés, Daniel
AU - Sandino, Ana María
AU - Imarai, Mónica
AU - Acuña-Castillo, Claudio
PY - 2022
Y1 - 2022
N2 - CoronaVac vaccine from Sinovac Life Science is currently being used in several countries. In Chile, the effectiveness of preventing hospitalization is higher than 80% with a vaccination schedule. However, to date, there are no data about immune response induction or specific memory. For this reason, we recruited 15 volunteers without previous suspected/diagnosed COVID-19 and with negative PCR over time to evaluate the immune response to CoronaVac 28 and 90 days after the second immunization (dpi). The CoronaVac administration induces total and neutralizing anti-spike antibodies in all vaccinated volunteers at 28 and 90 dpi. Furthermore, using ELISpot analysis to assay cellular immune responses against SARS-CoV-2 spike protein, we found an increase in IFN-gamma- and Granzyme B-producing cells in vaccinated volunteers at 28 and 90 dpi. Together, our results indicate that CoronaVac induces a robust humoral immune response and cellular immune memory of at least 90 dpi.
AB - CoronaVac vaccine from Sinovac Life Science is currently being used in several countries. In Chile, the effectiveness of preventing hospitalization is higher than 80% with a vaccination schedule. However, to date, there are no data about immune response induction or specific memory. For this reason, we recruited 15 volunteers without previous suspected/diagnosed COVID-19 and with negative PCR over time to evaluate the immune response to CoronaVac 28 and 90 days after the second immunization (dpi). The CoronaVac administration induces total and neutralizing anti-spike antibodies in all vaccinated volunteers at 28 and 90 dpi. Furthermore, using ELISpot analysis to assay cellular immune responses against SARS-CoV-2 spike protein, we found an increase in IFN-gamma- and Granzyme B-producing cells in vaccinated volunteers at 28 and 90 dpi. Together, our results indicate that CoronaVac induces a robust humoral immune response and cellular immune memory of at least 90 dpi.
KW - CoronaVac
KW - SARS-CoV-2
KW - Herd immunity
KW - Neutralizing antibodies
KW - COVID-19
KW - Vaccine
KW - Immunological memory
UR - https://www.scopus.com/pages/publications/85124612312
U2 - 10.3389/fimmu.2021.766278
DO - 10.3389/fimmu.2021.766278
M3 - Article
C2 - 35173705
SN - 1664-3224
VL - 12
JO - Frontiers in Immunology
JF - Frontiers in Immunology
ER -
